Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2007 (2007), Article ID 50180, 5 pages
http://dx.doi.org/10.1155/2007/50180
Research Article

Radioiodine Labeled Anti-MIF McAb: A Potential Agent for Inflammation Imaging

1Department of Nuclear Medicine, Qilu Hospital of Shandong University, Jinan 250012, China
2Institute of Experimental Nuclear Medicine, School of Medicine, Shandong University, Jinan 250012, China

Received 21 June 2007; Accepted 22 August 2007

Copyright © 2007 Chao Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. R. Bloom and B. Bennett, “Mechanism of a reaction in vitro associated with delayed-type hypersensitivity,” Science, vol. 153, no. 3731, pp. 80–82, 1966. View at Publisher · View at Google Scholar
  2. J. R. David, “Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 56, no. 1, pp. 72–77, 1966. View at Publisher · View at Google Scholar
  3. J. Bernhagen, T. Calandra, R. A. Mitchell et al., “MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia,” Nature, vol. 365, no. 6448, pp. 756–759, 1993. View at Publisher · View at Google Scholar
  4. C. M. Denkinger, C. Metz, G. Fingerle-Rowson, M. D. Denkinger, and T. G. Forsthuber, “Macrophage migration inhibitory factor and its role in autoimmune diseases,” Archivum Immunologiae et Therapiae Experimentalis, vol. 52, no. 6, pp. 389–400, 2004. View at Google Scholar
  5. T. Calandra and T. Roger, “Macrophage migration inhibitory factor: a regulator of innate immunity,” Nature Reviews Immunology, vol. 3, no. 10, pp. 791–800, 2003. View at Publisher · View at Google Scholar
  6. E. Lolis, “Glucocorticoid counter regulation: macrophage migration inhibitory factor as a target for drug discovery,” Current Opinion in Pharmacology, vol. 1, no. 6, pp. 662–668, 2001. View at Publisher · View at Google Scholar
  7. Y. P. De Jong, A. C. Abadia-Molina, A. R. Satoskar et al., “Development of chronic colitis is dependent on the cytokine MIF,” Nature Immunology, vol. 2, no. 11, pp. 1061–1066, 2001. View at Publisher · View at Google Scholar
  8. F. A. Bozza, R. N. Gomes, A. M. Japiassú et al., “Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis,” Shock, vol. 22, no. 4, pp. 309–313, 2004. View at Publisher · View at Google Scholar
  9. T. Ohkawara, J. Nishihira, H. Takeda et al., “Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice,” Gastroenterology, vol. 123, no. 1, pp. 256–270, 2002. View at Publisher · View at Google Scholar
  10. Y. Sakai, A. Masamune, A. Satoh, J. Nishihira, T. Yamagiwa, and T. Shimosegawa, “Macrophage migration inhibitory factor is a critical mediator of severe acute pancreatitis,” Gastroenterology, vol. 124, no. 3, pp. 725–736, 2003. View at Publisher · View at Google Scholar
  11. M. Leech, C. Metz, P. Hall et al., “Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids,” Arthritis and Rheumatism, vol. 42, no. 8, pp. 1601–1608, 1999. View at Publisher · View at Google Scholar
  12. N. Yabunaka, J. Nishihira, Y. Mizue et al., “Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes,” Diabetes Care, vol. 23, no. 2, pp. 256–258, 2000. View at Publisher · View at Google Scholar
  13. F. Nicoletti, A. Créange, D. Orlikowski et al., “Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain-Barré syndrome and experimental allergic neuritis,” Journal of Neuroimmunology, vol. 168, no. 1-2, pp. 168–174, 2005. View at Publisher · View at Google Scholar
  14. M. Niino, A. Ogata, S. Kikuchi, K. Tashiro, and J. Nishihira, “Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behçet’s disease,” Journal of the Neurological Sciences, vol. 179, no. 1-2, pp. 127–131, 2000. View at Publisher · View at Google Scholar
  15. C. J. van der Laken, O. C. Boerman, W. J. G. Oyen, M. T. P. van de Ven, J. W. M. van der Meer, and F. H. M. Corstens, “Scintigraphic detection of infection and inflammation: new developments with special emphasis on receptor interaction,” European Journal of Nuclear Medicine, vol. 25, no. 5, pp. 535–546, 1998. View at Publisher · View at Google Scholar
  16. W. Becker, “The contribution of nuclear medicine to the patient with infection,” European Journal of Nuclear Medicine, vol. 22, no. 10, pp. 1195–1211, 1995. View at Google Scholar
  17. S. Vinjamuri, A. V. Hall, K. K. Solanki et al., “Comparison of T99mc infecton imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection,” Lancet, vol. 347, no. 8996, pp. 233–235, 1996. View at Publisher · View at Google Scholar
  18. E. P. Krenning, D. J. Kwekkebomm, S. Pauwels, L. K. Kvols, and J. C. Reubi, “Somatostatin receptor scintigraphy,” in Nuclear Medicine Annual, pp. 1–50, Raven Press, New York, NY, USA, 1995. View at Google Scholar
  19. M. R. Plucher and P. J. Blower, “Labelling of lekocytes with colloidal tecnetium-99m-SnF2: an investigation of the labeling process by autoradiography,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 22, no. 2, pp. 101–107, 1995. View at Publisher · View at Google Scholar
  20. G. Ferro-Flores, C. Arteaga de Murphy, M. Pedraza-López et al., “In vitro and in vivo assessment of T99mc-UBI specificity for bacteria,” Nuclear Medicine and Biology, vol. 30, no. 6, pp. 597–603, 2003. View at Publisher · View at Google Scholar
  21. G. W. Visser, R. P. Klok, J. W. K. Gebbinck, T. Ter Linden, G. A. van Dongen, and C. F. Molthoff, “Optimal quality I131-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN,” Journal of Nuclear Medicine, vol. 42, no. 3, pp. 509–519, 2001. View at Google Scholar
  22. G. C. Jayson, J. Zweit, A. Jackson et al., “Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies,” Journal of the National Cancer Institute, vol. 94, no. 19, pp. 1484–1493, 2002. View at Publisher · View at Google Scholar
  23. I. Verel, G. W. M. Visser, R. Boellaard et al., “Quantitative Z89r immuno-PET for in vivo scouting of Y90-labeled monoclonal antibodies in xenograft-bearing nude mice,” Journal of Nuclear Medicine, vol. 44, no. 10, pp. 1663–1670, 2003. View at Google Scholar
  24. E. F. Morand, “New therapeutic target in inflammatory disease: macrophage migration inhibitory factor,” Internal Medicine Journal, vol. 35, no. 7, pp. 419–426, 2005. View at Publisher · View at Google Scholar
  25. D. Aeberli, M. Leech, and E. F. Morand, “Macrophage migration inhibitory factor and glucocorticoid sensitivity,” Rheumatology, vol. 45, no. 8, pp. 937–943, 2006. View at Publisher · View at Google Scholar